Drug-delivery endovascular stent and method for treating restenosis
US7682387B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Mar 5, 2003 |
| Grant date | Mar 23, 2010 |
| Priority date | — |
| Expiry date | Mar 5, 2023 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61L2300/606
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
An intravascular stent and method for inhibiting restenosis, following vascular injury, is disclosed. The stent has an expandable, linked-filament body and a drug-release coating formed on the stent-body filaments, for contacting the vessel injury site when the stent is placed in-situ in an expanded condition. The coating releases, for a period of at least 4 weeks, a restenosis-inhibiting amount of the macrocyclic triene immunosuppressive compound everolimus. The stent, when used to treat a vascular injury, gives good protection against clinical restenosis, even when the extent of vascular injury involves vessel overstretching by more than 30% diameter. Also disclosed is a stent having a drug-release coating composed of (i) 10 and 60 weight percent poly-dl-lactide polymer substrate and (ii) 40–90 weight percent of an anti-restenosis compound, and a polymer undercoat having a thickness of between 1–5 microns.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.